<DOC>
	<DOCNO>NCT01239134</DOCNO>
	<brief_summary>TRX518-001 open label , non-randomized single group assignment , Phase 1 single dose escalation study adult biopsy proven unresectable Stage III Stage IV melanoma solid tumor malignancy . Part A : The study objectives determine safety , tolerability , pharmacokinetic ( PK ) pharmacodynamic ( PD ) profile TRX518 define maximum tolerate dose tolerable side effect and/or maximum PK/PD parameter change . Subjects assign cohort order screen complete . Dose depend upon cohort subject enrol cohort dose consecutively ascend dose . Part A complete . Part B : A Dose-Escalation Study Multi-dose TRX518 Monotherapy objectives include characterization safety , tolerability , pharmacokinetics , well , evaluate evidence anti-tumor activity ass TRX518 immunogenicity . Part C : An Expansion Cohort Multi-dose TRX518 Monotherapy Maximum Tolerated Dose</brief_summary>
	<brief_title>Trial TRX518 ( Anti-GITR mAb ) Stage III IV Malignant Melanoma Other Solid Tumors</brief_title>
	<detailed_description>The following visit require : Part A : - Screening visit : 1 2 appointment conduct determine eligibility . All requirement determine patient 's medical record . - Baseline visit : within 7 day plan study dose day baseline physical exam , blood test electrocardiogram obtain . - Dosing visit : 1 outpatient visit TRX518 give IV 1 hour follow 4 hour observation repeat blood test . - Follow visit : 5 outpatient visit follow dose 1 , 8 15 day 3 , 6 , 12 , 18 week post dose - Long term follow-up : 4 brief assessment medical record review and/or telephone contact 6 , 12 , 18 , 24 month post dose . - The core study duration 18 week . The follow-up study duration 24 month . Parts B &amp; C : - Screening/Baseline visit : 1 appointment conduct perform test evaluation eligibility within 28 day first dose day . - Dosing Visits : Each subject receive IV dos TRX518 every week ( e.g. , D1 D15 ) 28-day cycle - Follow visit : When patient stop treatment , enter Follow-up Period End Treatment study visit approximately 30 day last dose study drug . Subsequently , patient long-term follow-up approximately every 12 week death lose follow .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion Criteria ( Parts B &amp; C ) : 18 year old Histologically confirm unresectable Stage III Stage IV malignant melanoma , solid tumor malignancy Failed respond relapse follow standard treatment , decline eligible standard treatment . Expected survival least 12 week . Eastern Cooperative Oncology Group performance status score 0 1 require . Evidence adequate organ function standard laboratory test . Exclusion Criteria ( Parts B &amp; C ) : Evidence progression central nervous system ( CNS ) metastases symptomatic CNS metastasis within 35 day prior dose . Ocular melanoma metastasize presence nonsolid tumor . A history major surgery within 4 week prior dose . Any history antitumor therapy complete within 28 day prior dose . Subjects active autoimmune disease history know suspect autoimmune disease , exception subject isolate vitiligo , resolve childhood asthma/atopy , psoriasis require systemic treatment control thyroid disorder . Clinically significant heart disease , define NYHA Class III IV . Any significant systemic infection require IV antibiotic . Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCAb ) unless HCV RNA undetected/negative . Treatment antihuman GITR monoclonal antibody ( mAb ) immunomodulatory therapy 42 day prior dose ( 30 day Interleukin2 &amp; Interferonα , 7 day Topical Imiquimod ) . Adverse event prior anticancer therapy resolve grade ≤1 except alopecia , vitiligo , endocrinopathy manage replacement therapy . Use investigational drug within 30 day prior dose . Any condition require likely require treatment pharmacologic dos systemic corticosteroid . Subjects permit receive physiologic replacement corticosteroid therapy ( ≤ 10 mg prednisone daily ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Malignant melanoma</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Stage III Stage IV</keyword>
	<keyword>Solid tumor</keyword>
</DOC>